NewEdge Advisors LLC Increases Holdings in Guardant Health, Inc. (NASDAQ:GH)

NewEdge Advisors LLC increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,929 shares of the company’s stock after purchasing an additional 230 shares during the quarter. NewEdge Advisors LLC’s holdings in Guardant Health were worth $59,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. R Squared Ltd bought a new stake in shares of Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. bought a new stake in Guardant Health in the 4th quarter worth approximately $43,000. Kimelman & Baird LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $58,000. Quantbot Technologies LP bought a new stake in Guardant Health in the fourth quarter worth $80,000. Finally, Jones Financial Companies Lllp boosted its holdings in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after acquiring an additional 817 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on GH. Barclays increased their price target on shares of Guardant Health from $55.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday. The Goldman Sachs Group lifted their price target on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Stifel Nicolaus upped their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, UBS Group raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday. Twenty-one investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and a consensus target price of $51.64.

Guardant Health Stock Down 4.1 %

GH stock opened at $46.85 on Friday. Guardant Health, Inc. has a twelve month low of $18.01 and a twelve month high of $52.92. The stock has a market cap of $5.78 billion, a P/E ratio of -13.16 and a beta of 1.45. The business’s 50-day moving average price is $43.74 and its 200-day moving average price is $38.23.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. During the same period last year, the firm earned ($0.46) earnings per share. The business’s quarterly revenue was up 20.8% on a year-over-year basis. On average, equities research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.